Literature DB >> 23186629

Highly active anti-hepatitis C therapy: seven lessons from HIV.

David L Thomas1.   

Abstract

The HCV direct-acting antiviral treatment era is underway. Although there are some important differences, it is likely that the experience with HCV will be similar in many respects to what already occurred with HIV. This paper considers seven important lessons learned with HIV and the degree to which they should be anticipated with HCV.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23186629      PMCID: PMC3715614          DOI: 10.3851/IMP2429

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  26 in total

1.  Age at cancer diagnosis among persons with AIDS in the United States.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Eric A Engels
Journal:  Ann Intern Med       Date:  2010-10-05       Impact factor: 25.391

2.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

Review 3.  Resistance to direct antiviral agents in patients with hepatitis C virus infection.

Authors:  Christoph Sarrazin; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2009-12-16       Impact factor: 22.682

4.  Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study.

Authors:  Kenneth A Lichtenstein; Carl Armon; Kate Buchacz; Joan S Chmiel; Kern Buckner; E M Tedaldi; Kathy Wood; Scott D Holmberg; John T Brooks
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

5.  Curing hepatitis C with pills: a step toward global control.

Authors:  David L Thomas
Journal:  Lancet       Date:  2010-10-14       Impact factor: 79.321

6.  Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.

Authors:  Juan Berenguer; Julio Alvarez-Pellicer; Pilar Miralles Martín; José López-Aldeguer; Miguel Angel Von-Wichmann; Carmen Quereda; Josep Mallolas; José Sanz; Cristina Tural; José María Bellón; Juan González-García
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

7.  Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

Authors:  Bart J Veldt; E Jenny Heathcote; Heiner Wedemeyer; Juerg Reichen; W Peter Hofmann; Stefan Zeuzem; Michael P Manns; Bettina E Hansen; Solko W Schalm; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2007-11-20       Impact factor: 25.391

8.  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

Authors:  Gary L Davis; Miriam J Alter; Hashem El-Serag; Thierry Poynard; Linda W Jennings
Journal:  Gastroenterology       Date:  2009-10-25       Impact factor: 22.682

9.  Opt-out testing for human immunodeficiency virus in the United States: progress and challenges.

Authors:  John G Bartlett; Bernard M Branson; Kevin Fenton; Benjamin C Hauschild; Veronica Miller; Kenneth H Mayer
Journal:  JAMA       Date:  2008-08-27       Impact factor: 56.272

10.  Public health impact of antiviral therapy for hepatitis C in the United States.

Authors:  Michael L Volk; Rachel Tocco; Sameer Saini; Anna S F Lok
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.